Ge Long Hui·2025-08-12 10:08Core Viewpoint - China Biopharmaceutical (01177.HK) has received acceptance for the clinical trial application (IND) of its innovative drug TQB3142, a Bcl-xL PROTAC molecule, from the National Medical Products Administration (NMPA) in China, aimed at treating malignant tumors [1] Group 1: Drug Mechanism and Efficacy - TQB3142 targets the degradation of the Bcl-xL protein through the ubiquitin-proteasome system, which alleviates its inhibition on tumor cell apoptosis, thereby activating the Caspase cascade and inducing programmed cell death in tumor cells [1] - The drug has shown significant anti-tumor activity in various transplantation tumor models and has a lower risk of platelet toxicity compared to similar candidate drugs, indicating a better therapeutic window and controllable metabolic risks [1] Group 2: Market Position and Potential - Currently, there are no approved Bcl-xL inhibitors available globally, making TQB3142 a novel mechanism anti-tumor drug [1] - The optimization of molecular design in TQB3142 allows for the maintenance of degradation activity while reducing blood toxicity risks, potentially providing new treatment options for patients with malignant tumors [1]